Turbine and MSD Collaborate on AI Simulations for Cancer Research
Turbine has announced a research collaboration with MSD to simulate cancer patient populations that are difficult to treat, announced in a press release. The partnership aims to use Turbine's Simulated Cells™ technology to create virtual tumor models that closely resemble challenging disease subtypes.
The collaboration will focus on uncovering novel dependencies in these resistant tumor populations through millions of simulated experiments. This approach is intended to guide MSD's laboratory efforts in validating new drug targets, biomarkers, and combination therapies. Initially set for one year, the agreement allows MSD the option to extend access to Turbine's virtual lab and proprietary models.
Turbine's AI-driven simulations aim to overcome the limitations of traditional lab models by mimicking the complex biology of cancer in patients, potentially opening new avenues for treatment. This collaboration highlights the ongoing integration of AI in cancer research to accelerate the discovery of effective therapies.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 30 Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354 Sep 29 Truven launches MarketScan Snapshot for healthcare data checks Sep 29 Omega Healthcare Wins Gold in 2026 AI Breakthrough Awards Sep 29 Phylo Launches Target Atlas for Drug Target Prioritization Sep 29 ChromAgeNet Detects Aging Signs in Blood Stem Cell ImagesLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
LUNGevity Awards $2 Million for Lung Nodule Risk Studies
Linearis Joins Two Canadian AI Health Data Projects
AbbVie Partners With Valkai on AI Tools for Clinical Development
CAS and Novartis Partner on Reaction Data for AI Research
Sunthetics Joins $19.5M NSF Autonomous Lab Initiative
Daily AI Brief: the AI news that matters, in your inbox.